TACE and tyrosine kinase inhibitors with or without PD-1 inhibitors as first-line therapy for intermediate-advanced HCC: a multicenter real-world cohort study. - Yang XG; Deng LW; Zhao Y; Peng B; Liu B; Feng SF; Liu DX; Liu JF; Sun YY; Chen Y; Liao CL; Zhang C; et al. (Hepatology international, 2026)